Hamlet BioPharma receives U.S. FDA Fast Track designation for Alpha 1H for the treatment of non-muscle invasive bladder cancer
Lund, Sweden, November 29, 2023. Hamlet BioPharma AB (publ), the pharmaceutical company with a strong portfolio of projects for the treatment of cancer and infections, announces today that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for its drug candidate Alpha1H for the treatment of non-muscle invasive bladder cancer. The U.S. FDA Fast Track Designation...
Dela artikeln
Taggar: hamlet, biopharma, receives
Läs vidare på Dagens IndustriRelaterade nyheter
- Hamlet Pharma ska göra företrädesemission till 25 procents rabatt
- Kallelse till årsstämma i Hamlet BioPharma AB
- ”Titta Hamlet” är ett mirakel som barnteater
- Hamlet Pharma secures long-term Alpha1 peptide production in an agreement with Polypeptide Group
- Hamlet Pharma soon to be Hamlet BioPharma presents at Aktiespararnas Capital Market Day on June 12 in Stockholm at 13.30 CET
Fler ekonominyheter
- Hamlet Pharma ska göra företrädesemission till 25 procents rabatt
- Kallelse till årsstämma i Hamlet BioPharma AB
- ”Titta Hamlet” är ett mirakel som barnteater
- Hamlet Pharma secures long-term Alpha1 peptide production in an agreement with Polypeptide Group
- Hamlet Pharma soon to be Hamlet BioPharma presents at Aktiespararnas Capital Market Day on June 12 in Stockholm at 13.30 CET